Details of Disease

Disease Name

Primary peritoneal carcinoma

Extra-ovarian primary peritoneal carcinoma; PPC; EOPPC; primary peritoneal cancer; primary peritoneal serous carcinoma; primary peritoneal carcinoma; primary peritoneal carcinoma (disease); serous surface papillary carcinoma

Definition

A rare carcinoma that arises from the peritoneum and resembles the malignant surface epithelial-stromal tumors that arise from the ovary. Serous adenocarcinoma is the most common histologic variant. It affects women almost exclusively. The diagnosis of primary peritoneal carcinoma can be made only if both ovaries are not involved by tumor, or, if the ovaries are involved, the tumor is confined to the ovarian surface without invasion of the ovarian stroma and the peritoneal involvement is greater than the ovarian surface involvement.

Disease Hierarchy

DISMNJQV: Peritoneal carcinomatosis

DISKYEDV: Primary peritoneal carcinoma

Disease Identifiers

MONDO ID

MONDO_0015686

UMLS CUI

C1514428

MedGen ID

269516

HPO ID

HP:0030406

Orphanet ID

168829

General Information of Disease (ID: DISKYEDV)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cisplatin	DMRHGI9	Approved	Small molecular drug	[1]
Paclitaxel	DMLB81S	Approved	Small molecular drug	[2]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 3 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BRCA2	TTUARD6	Limited	Genetic Variation	[3]
DPEP1	TTYUENF	moderate	Biomarker	[4]
PARP2	TTQ4V96	moderate	Genetic Variation	[5]
------------------------------------------------------------------------------------

This Disease Is Related to 3 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
DNAJC14	OT7DPIVN	moderate	Biomarker	[6]
SCARA3	OT46I38Y	moderate	Altered Expression	[7]
BRCA1	OT5BN6VH	Strong	Genetic Variation	[8]
------------------------------------------------------------------------------------

References

1	Cisplatin FDA Label
2	Paclitaxel FDA Label
3	BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer.Cancer. 2016 Jan 1;122(1):84-90. doi: 10.1002/cncr.29707. Epub 2015 Oct 6.
4	Multiple Heterotopic Ossification of the Intestine Detected by 99mTc-MDP Bone Scan in a Patient With Primary Peritoneal Cancer.Clin Nucl Med. 2018 Oct;43(10):749-751. doi: 10.1097/RLU.0000000000002234.
5	Niraparib: First Global Approval.Drugs. 2017 Jun;77(9):1029-1034. doi: 10.1007/s40265-017-0752-y.
6	Dopamine D1 receptor density in the mPFC responds to cognitive demands and receptorturnover contributes to general cognitive ability in mice.Sci Rep. 2018 Mar 14;8(1):4533. doi: 10.1038/s41598-018-22668-0.
7	SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions.Hum Pathol. 2012 May;43(5):669-74. doi: 10.1016/j.humpath.2011.06.003. Epub 2011 Aug 19.
8	Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study.Oncology. 2017;93(6):377-386. doi: 10.1159/000479155. Epub 2017 Aug 26.